Pharmaceutical Executive-04-01-2021

States and institutions are enacting mandates requiring greater inclusion of women and underrepresented groups on corporate boards; what are the key questions for pharma?

The “blank-check” method has emerged as a worthwhile bet for biopharma companies looking to raise capital and go public, but will its attractiveness fade along with the pandemic?

Life sciences companies uniquely tasked with meeting continuous and complex compliance-reporting requirements.

New data comparing past vs. present experience with telemedicine during the pandemic uncovers insight on how patients, doctors, and payers view the market post-COVID.

Click the title above for a link to open the Pharmaceutical Executive April 2021 issue in an interactive PDF format.

More capital gains and the potential strains for rest of 2021.

The Healthcare Businesswomen’s Association again names Sandra Horning its WoTY—where the pharma leader’s message of purpose and partnership takes on added resonance today.

Looking Back at 1990-1993.

Ethics and diversity on full display across pharma industry.

Building on early achievements as a research scientist and drug inventor, Rod MacKenzie, today the leader of global product development at Pfizer—and latest HBA Honorable Mentor—has devoted much of his career to helping others succeed, including advancing efforts to break down gender barriers in pharma.

A coalition of data, computational power, and AI is bringing the full potential of in silico medicine out of the realm of science fiction.

Draft plan looks beyond the immediate European health challenges.

Writing at the intersection of managed markets and the pharmaceutical industry.

How open, two-way communication can help leaders to improve.

Agency faces a significant backlog in the US and abroad.